[1]张婷,尹哲,杨阳,等.柏薏颗粒对高尿酸血症大鼠的初步药效学分析[J].华侨大学学报(自然科学版),2020,41(6):791-796.[doi:10.11830/ISSN.1000-5013.202006021]
　ZHANG Ting,YIN Zhe,YANG Yang,et al.Preliminary Pharmacodynamic Analysis of Baiyi Granules on Hyperuricemia Rats[J].Journal of Huaqiao University(Natural Science),2020,41(6):791-796.[doi:10.11830/ISSN.1000-5013.202006021]
点击复制

柏薏颗粒对高尿酸血症大鼠的初步药效学分析()
分享到：

《华侨大学学报（自然科学版）》[ISSN:1000-5013/CN:35-1079/N]

卷:
第41卷
期数:
2020年第6期
页码:
791-796
栏目:
出版日期:
2020-11-20

文章信息/Info

Title:
Preliminary Pharmacodynamic Analysis of Baiyi Granules on Hyperuricemia Rats
文章编号:
1000-5013(2020)06-0791-06
作者:
张婷1;  尹哲1;  杨阳1;  吴振2;  王立强1
1. 华侨大学 医学院, 福建 泉州 362021;2. 厦门大学 药学院, 福建 厦门 361102
Author(s):
ZHANG Ting1;  YIN Zhe1;  YANG Yang1;  WU Zhen2;  WANG Liqiang1
1. School of Medicine, Huaqiao University, Quanzhou 362021, China; 2. School of Pharmaceutical Sciences, Xiamen University, Xiamen 361102, China
关键词:
柏薏颗粒;  高尿酸血症;  黄嘌呤氧化酶;  药效学
Keywords:
Baiyi granule;  hyperuricemia;  xanthine oxidase;  pharmacodynamics
分类号:
R971.1;R285.5
DOI:
10.11830/ISSN.1000-5013.202006021
文献标志码:
A
摘要:
针对高尿酸血症大鼠模型开展柏薏颗粒的初步药效学研究,探究其作用机制.将72只雄性大鼠随机分为空白组、模型组、柏薏颗粒高、中、低剂量组及非布司他阳性对照组,采用氧嗪酸钾灌胃给药法建立高尿酸血症大鼠模型,连续给药治疗14 d,每天1次.采用酶联免疫吸附剂测定(ELISA)试剂盒测定血清尿酸(SUA)、肌酐(Cr)、尿素氮(BUN)水平及肝脏黄嘌呤氧化酶(XOD)活性,并用免疫印迹法测定肾脏中有机阴离子转运体1(OAT1)及葡萄糖转运体9(GLUT9)的表达.结果表明:与模型组相比,柏薏颗粒可剂量依赖性地降低SUA水平、肝脏XOD活性及GLUT9蛋白表达,并上调OAT1蛋白表达,且高剂量组与非布司他作用相当(P>0.05);柏薏颗粒组与空白组大鼠血清中Cr和BUN浓度无显著性差异,表明柏薏颗粒无肾损伤;柏薏颗粒具有明显的降血尿酸作用,其机制可能与抑制XOD活性和肾脏GLUT9蛋白表达,并上调OAT1蛋白表达有关.
Abstract:
Based on the rat model of hyperuricemia, a preliminary study on the pharmacodynamics of Baiyi granule was carried out and its mechanism was explored. 72 male rats were randomly divided into control group, model group, Baiyi granule high, medium and low dose groups and febuxostat positive control group. The rats were induced hyperuricemia through intragastric administration of oxonic aid potassium salt, and then administrated drugs by gavage, once a day for 14 consecutive days. The levels of uric acid(SUA), serum creatinine(Cr), urea nitrogen(BUN)and the xanthine oxidase(XOD)activity in liver were determined by enzyme linked immunosorbent assay(ELISA)kits, and the organic anion transporter 1(OAT1)and glucose transporter 9(GLUT9)proteins expressions in kidney were determined by western blot. Compared with themodel group, Baiyi granules can reduce the SUA level and liver XOD activity as well as GLUT9 protein expression in a dose-dependent manner, and up-regulate the OAT1 protein expression, and the high-dose group has the same effect as febuxostat(P>0.05). There is no significant difference in the contents of Cr and BUN in serum between Baiyi granule groups and control group, which indicates that Baiyi granule has no renal injury. In addition, Baiyi granules have obvious effect on reducing SUA, and its mechanism may be related to the inhibition of XOD activity and the expression of GLUT9 protein in kidney, and the up-regulation of OAT1 protein expression.

参考文献/References:

[1] 何青.高尿酸血症[M].北京:人民卫生出版社,2016.
[2] SOLTANI Z,RASHEED K,KAPUSTA D R,et al.Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: Is it time for reappraisal?[J].Curr Hypertens Rep,2013,15(3):175-181.DOI:10.1007/s11906-013-0344-5.
[3] 吕雪霞,胡吉东.高尿酸血症患病率调查及临床影响分析[J].临床检验杂志(电子版),2020,9(1):34-35.
[4] 杨丽华,刘晓丽,蒋雅琼,等.我国痛风的患病率及危险因素[J].医学研究杂志,2019,48(12):4-10.
[5] 尹相林,姚嵩坡,李兴洲,等.痛风和高尿酸血症发病的危险因素[J].中国老年学杂志,2020,40(10):2041-2044.
[6] CHEN J H,CHUANG S Y,CHEN H J,et al.Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: A Chinese cohort study[J].Arthritis Care and Research,2009,61(2):225-232.DOI:10.1002/art.24164.
[7] 郭立新.无症状高尿酸血症合并心血管疾病诊治建议中国专家共识解读[J].中国实用内科杂志,2011,31(4):271-273.
[8] 陈晓婷,陈海冰.高尿酸血症患者黄嘌呤氧化酶活性及影响因素分析[J].中华内分泌代谢杂志,2019,35(12):1050-1054.DOI:10.3760/cma.j.issn.1000-6699.2019.12.010.
[9] 肖峰.非布司他与别嘌醇治疗痛风的疗效及其安全性分析[J].中国社区医师,2018,34(3):56-58.DOI:10.3969/j.issn.1007-614x.2018.3.33.
[10] 许博洋,苏晓乐,乔晞.降尿酸治疗在控制慢性肾脏病进展方面的作用[J].国际泌尿系统杂志,2017,37(5):798-800.DOI:10.3760/cma.j.issn.1673-4416.2017.05.046.
[11] HOSOYA T,SASAKI T,HASHIMOTO H,et al.Clinical efficacy and safety of topiroxostat in Japanese male hyperuricemic patients with or without gout: An exploratory, phase 2a, multicentre, randomized, double-blind, placebo-controlled study[J].J Clin Pharm Ther,2016,41(3):298-305.DOI:10.1111/jcpt.12392.
[12] RICHETTE P,BARDIN T.Gout[J].Lancet,2010,375(9711):318-328.DOI:10.1016/S0140-6736(09)60883-7.
[13] 李裕明,闵洁,陈璐璐.促进尿酸排泄药物的疗效与安全性评价[J].药品评价,2015,12(7):45-49.DOI:10.3969/j.issn.1672-2809.2015.07.012.
[14] XU Liuqing,SHI Yingfeng,ZHUANG Shougang,et al.Recent advances on uric acid transporters[J].Oncotarget,2017,8(59):100852-100862.DOI:10.18632/oncotarget.20135.
[15] 程远磊,李飞.尿酸转运蛋白的研究现状[J].湖北医药学院学报,2017,36(5):470-473.DOI:10.13819/j.issn.1006-9674.2017.05.022.
[16] TAN P K,LIU Sha,GUNIC E,et al.Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout[J].Scientific Reports,2017,7(1):665.DOI:10.1038/s41598-017-00706-7.
[17] OTANI N,OUCHI M,HAYASHI K,et al.Roles of organic anion transporters(OATs)in renal proximal tubules and their localization[J].Anatomical Science International,2017,9(2):200-206.DOI:10.1007/s12565-016-0369-3.

相似文献/References:

[1]丁飞艳,郑茗冉,吴振,等.柏苓颗粒的降尿酸效果及其初步作用机制[J].华侨大学学报(自然科学版),2023,44(5):615.[doi:10.11830/ISSN.1000-5013.202301006]
　DING Feiyan,ZHENG Mingran,WU Zhen,et al.Effect of Bailing Granules on Reducing Uric Acid and Its Preliminary Action Mechanism[J].Journal of Huaqiao University(Natural Science),2023,44(6):615.[doi:10.11830/ISSN.1000-5013.202301006]

备注/Memo

备注/Memo:
收稿日期: 2020-06-12
通信作者: 王立强(1970-),男,教授,博士,主要从事药剂学与创新药物的研究.E-mail:wlq1599@163.com.
基金项目: 国家重点研发计划项目(2016YFE0101700); 福建省高校产学合作重大项目(2019Y4007); 华侨大学研究生科研创新基金资助项目(18014071025)http://www.hdxb.hqu.edu.cn
更新日期/Last Update: 2020-11-20